4//SEC Filing
Wells David R. 4
Accession 0001209191-19-060093
CIK 0001681682other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 5:54 PM ET
Size
10.4 KB
Accession
0001209191-19-060093
Insider Transaction Report
Form 4
Wells David R.
Chief Financial Officer
Transactions
- Award
Stock option (right to buy)
2019-12-11+138,375→ 138,375 totalExercise: $0.90Exp: 2029-12-11→ Common Stock (138,375 underlying) - Award
Series A Convertible Preferred Stock
2019-12-11$1143.68/sh+8.744$10,000→ 8.744 totalExercise: $0.87From: 2019-12-11→ Common Stock (10,051 underlying) - Award
Warrants
2019-12-11+10,051→ 10,051 totalExercise: $0.87From: 2019-12-11Exp: 2024-12-11→ Common Stock (10,051 underlying)
Footnotes (4)
- [F1]These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date.
- [F2]The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87.
- [F3]The Series A preferred stock has no expiration date.
- [F4]The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock.
Documents
Issuer
ENDRA Life Sciences Inc.
CIK 0001681682
Entity typeother
Related Parties
1- filerCIK 0001480371
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 5:54 PM ET
- Size
- 10.4 KB